Issue: Volume XXVIII, No. 17 - December 20, 2021

Congress Votes: No PAMA Price Cuts for 2022

IT’S WELCOME NEWS THAT CONGRESS VOTED EARLIER THIS MONTH to defer the PAMA price cuts to the Clinical Laboratory Fee Schedule (CLFS) that were scheduled to take place in 2022. This is a positive development for the finances of the nation’s clinical labs, particularly the smaller, independent labs that are often the only local labs …

Congress Votes: No PAMA Price Cuts for 2022 Read More »

2021’s Top 10 Lab Stories Confirm Important Trends

CEO SUMMARY: Much like 2020, the pandemic dominated our new list of the top 10 lab industry stories for 2021. Beyond COVID-19 testing, the virus crept its way into long-term trends, such as pathology jobs and technology innovation. New ways of delivering healthcare will need responses by clinical laboratories, as will significant developments in the …

2021’s Top 10 Lab Stories Confirm Important Trends Read More »

IVD Companies Report Record Sales as 2021 Draws to Close

JUDGING BY THE THIRD QUARTER FINANCIAL PERFORMANCE of the major in vitro diagnostics (IVD) manufacturers, the demand for COVID-19 testing continues to generate a substantial stream of revenue.  During their respective conference calls with investors and financial analysts, IVD company leaders associated revenue growth with increased sales of tests and supplies while noting the gradual …

IVD Companies Report Record Sales as 2021 Draws to Close Read More »

PAMA Test Price Cuts Deferred: It’s a ‘Huge Win’ for Labs

TWO BIPARTISAN VOTES IN THE U.S. HOUSE OF REPRESENTATIVES AND SENATE will save clinical laboratories from another year of deep payment cuts imposed under the Protecting Access to Medicare Act of 2014 (PAMA).  “This is a huge win for clinical labs,” said Erin Will Morton, Senior Vice President for Washington, D.C.-based CRD Associates. Morton represents …

PAMA Test Price Cuts Deferred: It’s a ‘Huge Win’ for Labs Read More »

Payers Continue to Increase Coverage of Liquid Biopsies

SINCE THE FIRST BLOOD-BASED, circulating-tumor DNA (ctDNA) sequencing test for cancer became available in 2014, federal and private payer coverage of these so-called “liquid biopsy” tests has increased substantially. Now, clinical laboratory and pathology directors can expect additional coverage as the clinical utility of these assays becomes more widely accepted.  The lead author of a …

Payers Continue to Increase Coverage of Liquid Biopsies Read More »

Theranos Lost $585 Mil. in 2015, Had Revenue of Just $500,000

AMONG THE BEST-KEPT SECRETS at Theranos during its glory days of 2013, 2014, and 2015—when the news media hailed now-disgraced founder and ex-CEO Elizabeth Holmes as a business genius to match Apple founder Steve Jobs—was the actual revenue the company was generating from its clinical laboratory testing activities.  No less a respected business magazine than …

Theranos Lost $585 Mil. in 2015, Had Revenue of Just $500,000 Read More »

December 20, 2021 Intelligence: Late-Breaking Lab News

In Europe, Switzerland-based Unilabs will be acquired by a Danish company. Unilabs owns laboratories in at least 11 European countries and posted revenue of €2 billion euros (US $2.26 billion) in the financial year ending September. The seller is Apax Partners, a private equity company in the United Kingdom. The buyer is A.P. Moller Holding, which …

December 20, 2021 Intelligence: Late-Breaking Lab News Read More »

;